Guy J. Lamarre

Array ( [id] => 20497632 [patent_doc_number] => 20260027089 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-01-29 [patent_title] => MrgprX2 Antagonists for the Treatment of Inflammatory Disorders [patent_app_type] => utility [patent_app_number] => 19/349768 [patent_app_country] => US [patent_app_date] => 2025-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29718 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19349768 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20377639 [patent_doc_number] => 20250360132 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-27 [patent_title] => METHODS OF ADMINISTERING MYOSIN INHIBITORS [patent_app_type] => utility [patent_app_number] => 19/287195 [patent_app_country] => US [patent_app_date] => 2025-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40417 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19287195 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20517572 [patent_doc_number] => 20260041675 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-02-12 [patent_title] => NASAL COMPOSITION [patent_app_type] => utility [patent_app_number] => 19/239326 [patent_app_country] => US [patent_app_date] => 2025-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6735 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19239326 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20686554 [patent_doc_number] => 12616682 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-05 [patent_title] => 1-H-pyrrolo[2,3-c]pyridine compounds [patent_app_type] => utility [patent_app_number] => 19/038137 [patent_app_country] => US [patent_app_date] => 2025-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 74333 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19038137 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20007343 [patent_doc_number] => 20250145565 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-08 [patent_title] => DITHIENYL DISULFIRAM DERIVATIVES AS SELECTIVE ALDH1A1 INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/985720 [patent_app_country] => US [patent_app_date] => 2024-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14616 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18985720 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19860686 [patent_doc_number] => 20250099472 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-27 [patent_title] => RUXOLITINIB FOR THE TREATMENT OF PRURIGO NODULARIS [patent_app_type] => utility [patent_app_number] => 18/973200 [patent_app_country] => US [patent_app_date] => 2024-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20464 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18973200 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20432512 [patent_doc_number] => 12502380 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-23 [patent_title] => MrgprX2 antagonists for the treatment of inflammatory disorders [patent_app_type] => utility [patent_app_number] => 18/923566 [patent_app_country] => US [patent_app_date] => 2024-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29774 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 291 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18923566 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19743933 [patent_doc_number] => 20250032498 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-30 [patent_title] => RUXOLITINIB FOR THE TREATMENT OF PRURIGO NODULARIS [patent_app_type] => utility [patent_app_number] => 18/912939 [patent_app_country] => US [patent_app_date] => 2024-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20463 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18912939 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19845158 [patent_doc_number] => 20250090509 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-20 [patent_title] => METHODS OF REDUCING ITCH USING TOPICAL ROFLUMILAST COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 18/884941 [patent_app_country] => US [patent_app_date] => 2024-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12595 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18884941 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19800450 [patent_doc_number] => 20250066375 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/812527 [patent_app_country] => US [patent_app_date] => 2024-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 74115 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 369 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18812527 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20443935 [patent_doc_number] => 20260000649 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-01-01 [patent_title] => TOPICAL FORMULATIONS FOR INFECTIONS [patent_app_type] => utility [patent_app_number] => 18/759222 [patent_app_country] => US [patent_app_date] => 2024-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27312 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18759222 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19510454 [patent_doc_number] => 20240342140 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => TOPICAL LIQUID COMPOSITIONS FOR TREATING HAIR LOSS [patent_app_type] => utility [patent_app_number] => 18/755647 [patent_app_country] => US [patent_app_date] => 2024-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5508 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18755647 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19496524 [patent_doc_number] => 20240335542 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-10 [patent_title] => NANOMATERIALS COMPRISING DISULFIDES [patent_app_type] => utility [patent_app_number] => 18/746787 [patent_app_country] => US [patent_app_date] => 2024-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44217 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -56 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18746787 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19601035 [patent_doc_number] => 20240391915 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-28 [patent_title] => CRYSTALLINE FORM OF TOLEBRUTINIB AND PREPARATION METHOD THEREOF [patent_app_type] => utility [patent_app_number] => 18/676250 [patent_app_country] => US [patent_app_date] => 2024-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6554 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18676250 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19448815 [patent_doc_number] => 20240308945 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => Synthetic Cannabinoid Compounds, Pharmaceutical Compositions, and Methods of Treating Anxiety and Other Disorders [patent_app_type] => utility [patent_app_number] => 18/672845 [patent_app_country] => US [patent_app_date] => 2024-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8386 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 258 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18672845 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19601047 [patent_doc_number] => 20240391927 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-28 [patent_title] => UNIFIED SYNTHETIC ENTRY TO AZASPIRO 3.N ALKANES [patent_app_type] => utility [patent_app_number] => 18/664869 [patent_app_country] => US [patent_app_date] => 2024-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22962 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18664869 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19430819 [patent_doc_number] => 20240299317 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => Fenfluramine for Treatment of Conditions Associated with Spreading Depolarization [patent_app_type] => utility [patent_app_number] => 18/663524 [patent_app_country] => US [patent_app_date] => 2024-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8927 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18663524 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20505038 [patent_doc_number] => 12539300 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-03 [patent_title] => Method of treating seizures and epilepsy using liquid pharmaceutical composition for oral dosage of vigabatrin [patent_app_type] => utility [patent_app_number] => 18/661306 [patent_app_country] => US [patent_app_date] => 2024-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4013 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18661306 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20492588 [patent_doc_number] => 12534450 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-27 [patent_title] => Methods and compositions for targeting PD-L1 [patent_app_type] => utility [patent_app_number] => 18/658848 [patent_app_country] => US [patent_app_date] => 2024-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 27446 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 297 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18658848 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19417270 [patent_doc_number] => 20240293393 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => RAMIPRIL SOLUTION FOR ORAL DOSAGE [patent_app_type] => utility [patent_app_number] => 18/652993 [patent_app_country] => US [patent_app_date] => 2024-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7943 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18652993 [rel_patent_id] =>[rel_patent_doc_number] =>)